Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia
Official title: Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial
Funded at Arkansas Children's Hospital Res Inst · NIH-11606535 · Data updated 2026-11-12
This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkansas Children's Hospital Res Inst NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $25,000 |
| NIH project number | 3R01AI170385-05S5 |
| Project ID | NIH-11606535 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pediatric patients (0-11 years old) with uncomplicated candidemia who show clinical improvement on initial echinocandin therapy.
✕Less likely to help
Children with complicated candidemia or whom current guidelines already require longer therapy may not benefit.
What this research studies
This multi-center randomized trial in children with invasive candidiasis asks if shortening antifungal therapy after an initial responsive period is safe and effective. All participants start on an echinocandin, with the question focused on whether an additional 7 days of therapy is necessary. The study compares outcomes between the shorter-duration approach and the standard 14-day total course. If successful, it could reduce treatment time, exposure to medications, and potential side effects for pediatric patients.
Why it matters
Potential benefit: If shorter therapy is non-inferior, children could have shorter hospital stays and fewer drug-related risks.
How similar studies have gone: Shorter durations have been shown safe for many bacterial infections, but this is a novel question for invasive fungal disease like candidemia.
Where this research is happening
-
Arkansas Children's Hospital Res Inst
Little Rock, United States Active
Researchers
- Principal investigator: Steinbach, William J — Arkansas Children's Hospital Res Inst
- Study coordinator: Steinbach, William J
Related research
Other NIH-funded projects on the same topics.
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
-
Shorter antifungal treatment for kids with candidemia
A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.
-
Shorter antifungal treatment for kids with candidemia
This study tests whether children with candidemia can finish treatment after 7 days of an echinocandin if they are improving, instead of completing a full 14 days.
-
Shorter antifungal course for kids with candidemia
A multi-center study tests whether 7 extra days of antifungal therapy after an initial week of treatment can be shortened safely for children with candidemia.
-
Shortened antifungal treatment for kids with candidemia
A pediatric multicenter trial will test whether stopping antifungal therapy after 7 more days, following an initial 7 days of treatment, isas safe as continuing for 14 days.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.